Clinical Trial Update: Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial evaluating the combination of cabozantinib (XL184) and nivolumab in patients with various advanced cancers and HIV; the study s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Kaposi Sarcoma
• Melanoma
• Non-small Cell Lung Cancer
• Ovarian Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• Cabometyx (cabozantinib)
• OPDIVO (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING